
AZD2014
CAS No. 1009298-59-2
AZD2014 ( Vistusertib )
产品货号. M10062 CAS No. 1009298-59-2
AZD2014 是一种新型 mTOR 抑制剂,无细胞测定中的 IC50 为 2.8 nM。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥348 | 有现货 |
![]() ![]() |
5MG | ¥551 | 有现货 |
![]() ![]() |
10MG | ¥964 | 有现货 |
![]() ![]() |
25MG | ¥1490 | 有现货 |
![]() ![]() |
50MG | ¥2017 | 有现货 |
![]() ![]() |
100MG | ¥3216 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称AZD2014
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述AZD2014 是一种新型 mTOR 抑制剂,无细胞测定中的 IC50 为 2.8 nM。
-
产品描述AZD2014 is a novel mTOR inhibitor with IC50 of 2.8 nM in a cell-free assay; highly selective against multiple PI3K isoforms (α/β/γ/δ). Phase 2.(In Vitro):The inhibitory effects of Vistusertib (AZD2014) are measured against isolated recombinant mTOR enzyme (IC50?of 2.81 nM) as well as in cellular assays measuring both mTORC1 and mTORC2 activities. In MDAMB468 cells, Vistusertib (AZD2014) decreases the phosphorylation of the mTORC1 substrate ribosomal protein S6 (Ser235/236) with a mean IC50?value of 210 nM and the mTORC2 substrate AKT (Ser473) with a mean IC50?value of 78 nM.(In Vivo):Vistusertib (AZD2014) induces dose-dependent tumor growth inhibition in several xenograft and primary explant models. The antitumor activity of Vistusertib (AZD2014) is associated with modulation of both mTORC1 and mTORC2 substrates, consistent with its mechanism of action. The pharmacokinetics of Vistusertib (AZD2014) in mice is tested upon administration of doses between 7.5 and 15 mg/kg. A dose-dependent increase in Cmax and AUC is observed following single dose and repeat dosing of AZD2014: Cmax range from 1 to 16 μM and AUC range from 220 to 5,042 μM·h across this dose range. The pharmacodynamic effect of Vistusertib (AZD2014) against an mTORC1 biomarker (phosphorylation of S6) and an mTORC2 biomarker (phosphorylation of AKT) is assessed in SCID mice bearing MCF7 xenografts following administration of 3.75, 7.5, and 15 mg/kg AZD2014. There is a good relationship between the drug plasma concentrations and biomarker levels (estimated p-AKT IC50 of 0.119 μM total, 53% SE, and estimated p-S6 IC50 0.392 μM, 28.8% SE).
-
体外实验——
-
体内实验——
-
同义词Vistusertib
-
通路PI3K/Akt/mTOR signaling
-
靶点Akt
-
受体P-Akt (S473)| mTOR| PI3Kα| pS6 (S235/236)
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number1009298-59-2
-
分子量462.54
-
分子式C25H30N6O3
-
纯度>98% (HPLC)
-
溶解度DMSO: 38 mg/mL (82.15 mM)
-
SMILESO=C(NC)C1=CC=CC(C2=CC=C3C(N4[C@@H](C)COCC4)=NC(N5[C@@H](C)COCC5)=NC3=N2)=C1
-
化学全称3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Sylvie M. Guichard, et al. Y Research: April 15, 2012; Volume 72, Issue 8, Supplement
产品手册




关联产品
-
Perifosine
一种口服生物可利用的烷基磷脂,在多种人类肿瘤模型中在体外和体内表现出显着的抗增殖活性;作为 Akt 抑制剂和 PI3K 抑制剂。
-
AZD-5363
AZD5363 是一种新型吡咯并嘧啶衍生化合物,可抑制所有 AKT 异构体 (IC50 <10 nM)。
-
Akt1Akt2-IN-17
一种有效的选择性 Akt1 和 Akt2 双重抑制剂,IC50 分别为 3.5 nM 和 42 nM。